<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073565</url>
  </required_header>
  <id_info>
    <org_study_id>VP-0601</org_study_id>
    <secondary_id>OMKK 02</secondary_id>
    <nct_id>NCT02073565</nct_id>
  </id_info>
  <brief_title>HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt</brief_title>
  <acronym>HARMONEE</acronym>
  <official_title>Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OrbusNeich Medical K.K.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OrbusNeich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single-blind, randomized, active-controlled, clinical trial in
      Percutaneous Coronary Intervention (PCI) subjects. Subjects will be randomized to receive the
      Combo stent as the investigational treatment arm or an Everolimus Eluting Stent (EES) as the
      active-control arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 50 sites are proposed in Japan and the United States to enroll 286 subjects (271
      evaluable) in each of 2 arms, for a total sample size of 572 subjects (542 evaluable) who are
      admitted to the hospital for a planned (elective and urgent) percutaneous coronary artery
      intervention procedure.

      After stent implantation, subjects will be contacted for follow-up at 30 days; 6 months; and
      1, 2, 3, 4, and 5 years. At 12 months a clinical evaluation will be completed before cardiac
      catheterization and angiographic assessment.

      Rationale: This study is intended to demonstrate that the Combo stent platform shows
      superiority to an imputed Bare Metal Stent (BMS) performance goal, noninferior effectiveness
      and safety vs best-in-class second-generation everolimus-eluting stent (EES) (Xience V,
      Xience Prime, Xience Xpedition stents; [Abbott Vascular/Abbott Vascular Japan]), and evidence
      of mechanistic activity of the anti-CD34-Ab endothelial progenitor cell (EPC) capture
      technology with healthy level of intimal tissue coverage superior to that of the
      best-in-class EES.

      To ensure the robustness and interpretability of results, the current proposal includes a
      number of unique design features:

        -  Largest randomized Drug-Eluting Stent (DES) study ever performed in Japan

        -  Enriched population, including stabilized Non-ST-elevation myocardial infarction
           (NSTEMI) subjects with greater likelihood of plaque rupture associated with their
           clinical syndromes

        -  Collaboration between with Japan and the United States as a &quot;Proof of Concept&quot; program
           under the auspices of the Harmonization by Doing Initiative, Working Group 1 (WG 1),
           including concomitant enrollment in U.S.A. sites as an FDA-approved Investigational
           Device Exemption (IDE) study

        -  Head-to-head randomization against state-of-the-art EES platform control, analyzed for
           clinical noninferiority

        -  Statistical analysis vs imputed BMS analyzed for clinical superiority

        -  Fractional flow reserve (FFR) follow-up of 100% of subjects enrolled, providing
           clinically relevant physiologic assessment of all subjects for 1 year ischemia-driven
           Target Vessel Revascularization (TVR) analysis

        -  Mechanistic Optical coherence tomography (OCT) imaging observations in 140 subjects
           using 6 French catheters as follows:

             -  Cohort A (30 subjects, 1:1 Combo and EES): Mechanistic imaging observations to
                provide serial 6 month and 1 year OCT evaluation of healthy intimal tissue
                coverage, intracoronary thrombosis, and stent malapposition and quantitative
                coronary angiographic (QCA) analysis to assess 1 year late loss.

             -  Cohort B (110 subjects, 1:1 Combo and EES): Mechanistic imaging observations to
                assess 1 year OCT evaluation of healthy intimal tissue coverage, intracoronary
                thrombosis, and stent malapposition, and QCA analysis to assess 1 year late loss.
                Combined with the 12 month imaging of Cohort A, this study will provide OCT and QCA
                observations at 1 year in 140 patients, half with Combo and half with EES.

             -  Cohort C: 432 subjects (216 subjects per arm) will undergo all clinical follow-up
                assessments with FFR and angiographic assessments at 12 months. Cohort C will be
                the last cohort to enroll.

        -  In the 110 subjects in Cohort B, 30 day and 1 year human antimurine antibody (HAMA)
           titers will also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Healthy Tissue Coverage That Was Greater Than 40 Micrometers</measure>
    <time_frame>1 year</time_frame>
    <description>The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With Clinically and Functionally Ischemia-Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients Exhibiting Human Antimurine Antibody (HAMA) Reaction</measure>
    <time_frame>Day of device implantation, 30 days, 12 months</time_frame>
    <description>Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">572</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Non ST Segment Elevation Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus Eluting Stent (EES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrbusNeich Combo stent™</intervention_name>
    <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
    <arm_group_label>Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus Eluting Stent (EES)</intervention_name>
    <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
    <arm_group_label>Everolimus Eluting Stent (EES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        To be eligible for this trial, subjects must meet all of the following criteria:

          1. Subject is able to verbally confirm understanding of risks, benefits, and treatment
             alternatives of Combo vs EES stent, and the subject or a legally authorized
             representative (LAR) must provide written informed consent before any study-related
             procedures are performed.

          2. Subject must be at least 20 years of age at the time of randomization.

          3. Subject must have clinical or functional evidence of myocardial ischemia (eg, stable
             or unstable angina, stabilized non-ST-elevation myocardial infarction confirmed by
             serum markers, ischemia by positive functional study, abnormal FFR, or a reversible
             change in the electrocardiogram (ECG) consistent with ischemia).

          4. Subject must be acceptable candidate with anatomy suitable for PCI with a DES.

          5. Subject agrees to return for all study-related follow-up assessments, including
             invasive OCT follow-up assessment at 6 months (Cohort A) and at 1 year postprocedure
             (Cohorts A, B, and C).

          6. Subject is an acceptable candidate for Coronary artery bypass grafting (CABG) surgery.

             Angiographic Anatomy Criteria—

          7. Target lesions must be located in a native coronary artery with visually estimated
             diameter of 2.5 mm to 3.5 mm, inclusive, and up to 3 de novo target lesions may be
             treated, with a maximum of 2 de novo target lesions per epicardial vessel, with a
             maximum of 2 target vessels.

          8. Target lesions should be treatable with a single stent, and must measure 28 mm or less
             in length by visual estimation (2 mm or more of nondiseased tissue on either side of
             the target lesion should be covered by the study stent).

          9. If more than 1 target lesion will be treated, the reference vessel diameter and lesion
             length of each target lesion must meet the above criteria.

         10. Target lesions must be in a major artery or branch with a visually estimated stenosis
             of 50% or greater and less than 100% with a Thrombolysis in Myocardial Infarction
             (TIMI) flow of 1 or greater.

         11. Previous percutaneous intervention of lesions in a target vessel (including side
             branches) is allowed if done 9 or more months before the study procedure and greater
             than 10 mm from the current target lesion.

         12. Nonstudy percutaneous interventions for lesions in a nontarget vessel are allowed if
             done 9 or more months before the study procedure, in the absence of documented
             ischemia or angiographic restenosis related to the vessel.

        Exclusion Criteria

        If a subject meets any of the following criteria, he or she may not be enrolled in the
        study:

          1. ST-Elevation Myocardial Infarction (STEMI) at index presentation or within 7 days of
             study screening.

          2. Subject has current unstable arrhythmias or intractable angina with ECG changes or
             shock requiring pressors or mechanical assist device (intraaortic balloon pump, left
             ventricular assist device, Impella, etc.).

          3. Subject has known left ventricular ejection fraction (LVEF) less than 30%.

          4. Subject has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant.

          5. Subject is receiving or scheduled to receive anticancer therapy for malignancy within
             30 days before or after the procedure.

          6. Subject is receiving immunosuppression therapy, has known serious immunosuppressive
             disease (eg, human immunodeficiency virus), or has severe autoimmune disease that
             requires chronic immunosuppressive therapy (eg, systemic lupus erythematosus).

          7. Subject has known hypersensitivity or contraindication to aspirin; both heparin and
             bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, ticlopidine, and
             ticagrelor); any everolimus, sirolimus, cobalt, chromium, nickel, tungsten, acrylic,
             or fluoro polymers; or hypersensitivity to contrast media that cannot be adequately
             premedicated.

          8. Subject has previously received murine therapeutic antibodies and exhibited
             sensitization through the production of human anti-mouse antibodies (HAMAs).

          9. Subject has elective surgery planned within the first 12 months after the procedure
             that will require interruption or discontinuation of planned Dual Antiplatelet Therapy
             (DAPT).

         10. Subject has known platelet count less than 100,000 cells/mm3 or greater than 700,000
             cells/mm3, a white blood cell count of less than 3000 cells/mm3, or documented or
             suspected liver disease (including laboratory evidence of hepatitis).

         11. Subject has known renal insufficiency (eg, serum creatinine level of greater than 2.5
             mg/dL or subject is on dialysis).

         12. Subject has history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

         13. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             within the past 6 months.

         14. Subject has had a significant gastrointestinal or urinary bleed within the past 6
             months.

         15. Subject has known extensive peripheral vascular disease that precludes safe 6 French
             sheath insertion.

         16. Known other medical illness (eg, cancer, chronic infectious disease, severe vascular
             disease, or congestive heart failure) or known history of substance abuse (alcohol,
             cocaine, heroin, etc.) that may cause noncompliance with the protocol, confound the
             data interpretation, or is associated with a life expectancy of less than 1 year.

         17. Currently participating in another clinical study that has not yet reached its primary
             endpoint.

         18. Currently pregnant or breast-feeding or is planning pregnancy in the period up to 1
             year following index procedure. Female subjects of childbearing potential must have a
             negative pregnancy test within 7 days before the index procedure.

             Angiographic Exclusion Criteria—

             If the target lesion meets any of the following criteria, the subject may not be
             enrolled in the study:

         19. Unprotected left main coronary artery location.

         20. Unprotected ostial (located within 2 mm of the origin) left anterior descending artery
             or left circumflex.

         21. Located within an arterial or saphenous vein graft or graft anastomosis, distal to a
             diseased arterial or saphenous vein graft (visually estimated graft diameter stenosis
             greater than 40%).

         22. Involves a bifurcation in which the side branch is 2 mm or greater in diameter AND
             would be covered by the planned stent.

         23. Involves a side branch requiring predilation.

         24. Total occlusion (TIMI flow 0) before wire crossing.

         25. Extreme tortuosity proximal to or within the lesion.

         26. Extreme angulation (90º or greater) proximal to or within the lesion.

         27. Heavy calcification, defined as multiple persisting opacifications of the coronary
             wall visible in more than one projection surrounding the complete lumen of the
             coronary artery at the site of the lesion.

         28. Restenotic vessel from previous intervention.

         29. Received brachytherapy in any epicardial vessel (including side branches).

         30. Target vessel contains angiographically visible thrombus.

         31. Serial lesions or diffuse disease with high probability of bailout requiring 3 or more
             stents in a single vessel, more than 5 stents per subject, or more than 2 vessels.

         32. Target or nontarget vessel lesion (including all side branches) is present with a high
             probability of requiring PCI within 12 months after the index procedure.

         33. Stent overlapping is a planned treatment of the target lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell W Krucoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedStar Clinical Research Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research Collaborative-Cardiology</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Heart Foundation</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center-Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Fukuoka General Hospital</name>
      <address>
        <city>Fukoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkoga Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiya General Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>730-655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakodate Municipal Hospital</name>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <zip>041-8680</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Brain and Heart Centre</name>
      <address>
        <city>Himeji-shi</city>
        <state>Hyogo</state>
        <zip>670-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takahashi Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashi Takarazuka Satoh Hospital</name>
      <address>
        <city>Takarazukasi</city>
        <state>Hyogo</state>
        <zip>665-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiura Kyodo Hospital</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <zip>300-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Cardiovascular Hospital</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>920-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organisation Kagoshima Medical Centre</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>892-0583</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Okamoto</city>
        <state>Kamakura City</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Tobu Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sakakibara Heart Institute of Okayama</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Saiseikai Nakatsu Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital</name>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Prefectural Cardiovascular and Respiratory Disease Centre</name>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama-ken</state>
        <zip>360-0197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okamura Memorial Hospital</name>
      <address>
        <city>Suntou-gun</city>
        <state>Shizouka</state>
        <zip>411-0904</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Juntendo University School of Medicine</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8421</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakakibara Memorial Hospital</name>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <zip>183-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Hospital</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>106-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Catheterisation Laboratory, Keio University School of Medicine</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kong DF, Saito S, Nakamura S, Mehran R, Rowland SM, Handler A, Al-Khalidi HR, Krucoff MW. Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. Am Heart J. 2017 May;187:112-121. doi: 10.1016/j.ahj.2017.02.004. Epub 2017 Feb 12.</citation>
    <PMID>28454795</PMID>
  </reference>
  <results_reference>
    <citation>Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, Rowland SM, Tasissa G, Morrell D, Joseph D, Okaniwa Y, Shibata Y, Bertolet BD, Rothenberg MD, Généreux P, Bezerra H, Kong DF. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J. 2018 Jul 7;39(26):2460-2468. doi: 10.1093/eurheartj/ehy275.</citation>
    <PMID>29931092</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <results_first_submitted>September 19, 2018</results_first_submitted>
  <results_first_submitted_qc>October 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2018</results_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracoronary stent</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>sirolimus</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02073565/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combo</title>
          <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
        </group>
        <group group_id="P2">
          <title>Everolimus Eluting Stent (EES)</title>
          <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intention-To-Treat Subjects-Cohorts AB&amp;C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cohort B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cohort C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combo</title>
          <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
        </group>
        <group group_id="B2">
          <title>Everolimus Eluting Stent (EES)</title>
          <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="572"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="9.6"/>
                    <measurement group_id="B2" value="66.5" spread="10.4"/>
                    <measurement group_id="B3" value="67.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian (non-Japanese)-</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japanese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-ST-segment elevation myocardial infarction (Non-STEMI) Presentation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multivessel Coronary Artery Disease (MV CAD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction (MI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Percutaneous Coronary Intervention (PCI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Coronary Artery Bypass Grafting (CABG)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diabetes: Insulin Dependent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diabetes: Non-insulin Dependent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants without Diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarette Smoking (current/former)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Renal Insufficiency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Dual Antiplatelet Therapy (DAPT) at 6 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Dual Antiplatelet Therapy (DAPT) at 1 year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Statins at 1 year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Beta-blockers at 1 year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year.</description>
        <time_frame>1 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combo</title>
            <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus Eluting Stent (EES)</title>
            <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Healthy Tissue Coverage That Was Greater Than 40 Micrometers</title>
        <description>The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers.</description>
        <time_frame>1 year</time_frame>
        <population>Cohorts A and B - Subjects with analyzable Optical coherence tomography (OCT) follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Combo</title>
            <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus Eluting Stent (EES)</title>
            <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Healthy Tissue Coverage That Was Greater Than 40 Micrometers</title>
          <description>The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers.</description>
          <population>Cohorts A and B - Subjects with analyzable Optical coherence tomography (OCT) follow-up</population>
          <units>Healthy Tissue Strut Coverage (&gt;40 µm) %</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.27" lower_limit="88.71" upper_limit="93.84"/>
                    <measurement group_id="O2" value="74.82" lower_limit="70.02" upper_limit="79.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Clinically and Functionally Ischemia-Driven Target Lesion Revascularization (TLR)</title>
        <description>Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combo</title>
            <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus Eluting Stent (EES)</title>
            <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically and Functionally Ischemia-Driven Target Lesion Revascularization (TLR)</title>
          <description>Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Exhibiting Human Antimurine Antibody (HAMA) Reaction</title>
        <description>Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations.</description>
        <time_frame>Day of device implantation, 30 days, 12 months</time_frame>
        <population>Cohort B - Please note that for the &quot;1 Year HAMA Responders&quot; Row in the Combo arm, 52 participants were analyzed (1 participant withdrew and 1 participant died). For the &quot;1 Year HAMA Responders&quot; Row in the EES arm, 52 participants were analyzed (2 participants withdrew and 2 participants were not present for the 1 year visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Combo</title>
            <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus Eluting Stent (EES)</title>
            <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Exhibiting Human Antimurine Antibody (HAMA) Reaction</title>
          <description>Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations.</description>
          <population>Cohort B - Please note that for the &quot;1 Year HAMA Responders&quot; Row in the Combo arm, 52 participants were analyzed (1 participant withdrew and 1 participant died). For the &quot;1 Year HAMA Responders&quot; Row in the EES arm, 52 participants were analyzed (2 participants withdrew and 2 participants were not present for the 1 year visit).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HAMA Responders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day HAMA Responders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year HAMA Responders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Per the protocol, all adverse events will be collected from the point of subject enrollment through the 1-year follow-up. All adverse events listed as protocol-specific endpoints (Death, Cardiac death, MI, Target vessel MI, TLR (ischemia driven), TVR (ischemia driven), Stroke, transient ischemic attack (TIA), and Stent Thrombosis (ARC definition)) will be collected from 1-year follow to the completion of the study at the 5-year follow-up. The data reported below is at 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combo</title>
          <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
OrbusNeich Combo stent™: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
        </group>
        <group group_id="E2">
          <title>Everolimus Eluting Stent (EES)</title>
          <description>Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Everolimus Eluting Stent (EES): Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Coronary artery disection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus management</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Debbie Morrell, Clinical Research Manager</name_or_title>
      <organization>OrbusNeich</organization>
      <phone>954-730-0711</phone>
      <email>DMorrell@OrbusNeich.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

